Our Partners

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.

Amgen Patient Resources:

Over the past four decades, Biogen has been committed to translating science to meaningful advances for the MS community. Our industry-leading portfolio — backed by established safety and efficacy profiles, ongoing investment in our products, as well as our comprehensive services and solutions — enables us to offer a broad range of options to meet the ever-evolving needs of MS patients and drive greater individualized disease management.

Biogen Patient Resources:

BALANCE-MSS-1 is a Phase 2 clinical trial evaluating an investigational oral treatment for spasticity in people living with multiple sclerosis (MS). Spasticity, which may cause muscle stiffness, spasms, and pain, can significantly impact daily activities and sleep.^(1,2) The BALANCE-MSS-1 trial is exploring a once-daily oral capsule to better understand its potential role in managing MS-related spasticity. Eligible adults with MS who have experienced spasticity for at least six months may be able to participate. The study may last up to 20 weeks and includes screening, treatment period, an optional extension, and follow-up. Qualified participants will receive study-related care at no cost, and travel reimbursement may be available.

Bristol Myers Squibb Patient Resources:

EMD Serono’s experience and scientific discoveries in MS date back more than 20 years. They have an ongoing commitment to improving the entire patient experience. To this end, they offer delivery devices for their therapeutic products as well as comprehensive patient education resources. It is the people living with MS or those who will be diagnosed with MS, their caregivers and healthcare providers who have been their catalyst and inspiration to continue innovating, collaborating and advocating.

EMD Serono Patient Resources:

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

Genentech Patient Resources:

Advancing research in MS is essential to address the ongoing needs of people living with the disease. Immunic Therapeutics is actively pursuing research and clinical development of novel, orally administered therapies, exploring new approaches to target biologically relevant pathways involved in relapsing and progressive forms of MS. Alongside scientific and clinical progress, collaboration across the MS community remains important to supporting and making a meaningful difference for people with MS. Immunic Therapeutics is proud to support Can Do MS and our shared mission to improve the quality of life for individuals with MS.

Immunic Therapeutics Patient Resources:

The Kathleen C. Moore Foundation is dedicated to funding research & resources to fight, cure & eliminate MS

Kathleen C. Moore Foundation Patient Resources:

NEU-ring is a diverse network of clinicians across academic institutions and private MS clinics with a decade of experience in collaborative research whose mission is to galvanize advances in women’s health research in neuroimmunological diseases through adaptive, flexible, national, and international collaborations in MS, NMOSD and MOGAD.

Neu-Ring Patient Resources:

Novartis brings innovative medicines to market to enhance health outcomes for patients and offer solutions to the healthcare providers who treat them. A clinical trial is a research experiment to find out how people respond to new medical treatments. Novartis has long been dedicated to informing the public about the results of its interventional trials for innovative products. A trial summary for patients is a trial result written in easier to understand language than the corresponding technical result summary. Novartis provides trial summaries for patients from Phase 1 through 4 interventional trials for innovative products. The trial summary for patients is provided in English and the local languages of the trial patients.

Novartis Patient Resources:

Built on patient insights and cutting-edge science and technology, Sanofi is determined to help people living with neurological disorders by developing new treatment options and advancing patient care. With 18 years’ commitment in multiple sclerosis (MS), Sanofi has relentlessly worked to improve the lives of the 2.3 million people worldwide living with this serious, life-long neuro-degenerative disease. Since the launch of its portfolio in 2012, Sanofi has rapidly emerged as a leader in MS, bringing two therapies to patients in more than 80 countries worldwide. There is significant work left to be done, and Sanofi is committed to accelerating the development of potential treatments for MS, amyotrophic later sclerosis, and other neurological diseases.

Sanofi Patient Resources:

Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose.

Sandoz Patient Resources:

We believe that the best solution for patients may not lie in a single drug but in a unique combination of medicines. TG Therapeutics was founded with one goal in mind—to leverage scientific advances in B-cell biology to develop novel treatments for patients. We’ve dedicated ourselves to this simple concept and to the study of B-cells and B-cell diseases. To achieve our goal, we search the globe looking for medicines in early research that we believe could be combined to create better treatment options for patients.

TG Therapeutics Patient Resources:

Zenas is evaluating orelabrutinib, an investigational medication, in two Global Phase 3 clinical research studies for adults living with progressive forms of multiple sclerosis (MS). These studies are being run to evaluate the safety and efficacy of orelabrutinib in slowing the progression of symptoms that affect daily life in adults living with primary progressive MS and non-active secondary progressive MS. Progressive forms of MS can lead to worsening symptoms that affect daily life, difficulties with walking, balance, coordination, strength, vision, and thinking or memory. Despite advances in treatments, there remains a need for additional therapies that can help slow the progression of the diseases.

Zenas BioPharma Patient Resources: